Despite the decline in adjusted operating margin and EPS due to tariffs, the company shows strong revenue performance, operational execution, and a commitment to share buybacks. The Q&A reveals no structural changes hindering growth, strong momentum in key areas, and a stable pricing environment. However, uncertainties in China and vaccine headwinds persist. Positive elements like R&D investments and a stable pricing environment are offset by tariff impacts and cautious guidance, leading to a neutral sentiment.